Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
56 Cards in this Set
- Front
- Back
Major sites of androgen synthesis
|
Adrenal cortex (zona reticularis)
Gonads (Testes) |
|
Where is the major site of production in women? men?
|
Adrenal gland
Testes |
|
What is androgen production controlled by?
|
ACTH
|
|
What are steroids synthesized from?
|
cholesterol
|
|
Which androgen does the adrenal produce most.
|
Dehydroepiandrosterone (DHEA)
|
|
What other minor products does the adrenal make.
|
Androstenedione
Androstenediol Testosterone |
|
What controls production of testosterone?
|
GnRH--LH--Leydig cells--Testosterone
|
|
What androgens are produced in the testes?
|
Testosterone
Dihydrotestosterone (DHT) DHEA (minor) Androstenedione |
|
What transports androgens?
|
Testosterone-estrogen binding protein (30%)
Albumin (68%) Free (2%) |
|
What is the active fraction?
|
AF = free + albumin-bound
|
|
MA of androgens
|
Pass through cell membrane
Bind to cytosolic receptors Activate specific genes |
|
Testosterone action
|
Acts at androgen receptors
Coverted to DHT in peripheral tissues Converted to estrogen in specific tissues (e.g. brain) |
|
Androgen production in males? Females?
|
95% testes, 5% adrenals
1/20 of males, equal synthesis in ovaries and adrenals |
|
5 actions of androgens
|
1. Growth and development
2. Development of male sex organs 3. Male sex drive and performance 4. Development of secondary sex characteristics 5. Spermatogenesis |
|
How do androgens act to develop male sex organs?
|
UG tract virilization by 2nd trimester testosterone increases
|
|
Testosterone and secondary sex characteristics
|
Seminiferous tubules, epididymus, vas deferens, muscle, larynx
|
|
DHT and secondary sex characteristics
|
External characteristics
Growth of penis, scrotum, pubic hair, sebaceous glands, and beard (later baldness) |
|
DHEA (converted to estrogen and testosterone) and secondary sex characteristics
|
Growth in adolescent females, important during fetal periods
|
|
Oral anabolics
|
modified at 17 alpha position
can cause liver damage |
|
Injectable androgens
|
Modified at 17 beta (prolongs absorption)
|
|
Side effects of abusing adrogens
|
Decreased libido
Impotence Testicular atrophy Gynecomastia Toxicity |
|
Congenital Adrenal Hyperplasia
|
21 hydroxylase def.
Increase ACTH, urinary metabolism of progesterone and plasma DHEA Precocious puberty in males, masculinization in post puberty females |
|
Pseudohermaphroditism and treatment
|
Lack 5 alpha reductase
T not converted to DHT Phenotype more female than male Treat with plastic surgery and estrogen |
|
Testicular feminization
|
external female phenotype
Adrogen binding site or DNA binding site mutations Aromatase in mammary tissues produces estrogen Leads to breast development in men |
|
Hypogonadism treatment
|
Injectable androgens need
Lg. doses need to induce spermatogenesis |
|
Andropause
|
Concentration of testosterone decreases 1-2%/yr after age 30
By 70 production reduced at least 50% |
|
What can therapy do for those w/andropause
|
Increased muscle strength
Increased libido Increased sense of well being |
|
What are the treatments for Andropause
|
Testoderm patch- taped to scrotum
Androderm patch Androgel- rubbed on shoulders |
|
Treatment for endometriosis or fibrocystic dz of the breast?
|
Danazol or Stanozol for 1-2 months
|
|
SE of Danazol or Stanozol
|
Facial and body hair
Deepening of voice-irreversible Clitoral enlargement-reversible |
|
Hereditary Angioedema and treatment
|
Impaired C1-esterase inhibitor--overactive complement--increased blood vessel permeablity
Orally active adrogen (e.g. danazol) |
|
How much of an androgen is needed to treat anemia?
|
Large doses
|
|
Adverse effects of androgen therapy
|
Percocious puberty
Premature closure of epiphyseal plates Virilization in women Jaundice |
|
name 4 Androgen Receptor Antagonists (ARAs)
|
1. Cyproterone acetate
2. Flutamine 3. Finasteride 4. Dutasteride |
|
Cyproterone acetate
|
Used for hirsutism in women
|
|
Flutamine
|
Used in metastatic prostate cancer
|
|
Finasteride MA and use
|
Blocks prostate 5 alpha reductase (no T---DHT)
BPH and baldness |
|
Dutasteride
|
Blocks 1 and 2 5 alpha reductase, effective in all tissues
|
|
Natural estrogens
|
Estradiol* main product of ovary
Estriol Estrone Premarin (from pregnant mare) |
|
What does estrogen do in the embryo
|
Formation of vagina
Formation of uterus and tubes |
|
Affects of estrogen
|
2nd sex characteristics
Stabilizes blood cells in skin Bone strength Promotes growth of uterus |
|
At puberty estrogen stimulates
|
Axillary pubic hair
Distribution of body fat Ductal and stroma development of breasts Endometrial development Growth of long bone and eventual closure |
|
Where are estriol and estrone produced?
|
Liver
|
|
Where can estrone be produced?
|
Male and female adipose tissue
|
|
Estrogen modified in the 17 alpha position does what?
Name two drugs like this |
1)Becomes orally active
2)Ethinyl estradiol and Mestanol |
|
Equine estrogens are usually conjugated w/what?
Name two drugs like this |
SO4- avoids first pass metab.
e.g. Equilenin and equilin(Premarin) |
|
When do you begin treatment for hypogonadism in women?
|
11-13 years
|
|
Menopausal symptoms and sequelae
|
Hot flashes
Memory problems Osteoporosis |
|
What risk does HRT increase?
|
MI (Increased HTN, decreased HDL)
|
|
Why was the estrogen-progesterone study halted?
|
Increased risk of MI, stroke, blood clots, and breast cancer
|
|
Why was the estrogen replacement study halted?
|
Increased risk of stroke and MI
|
|
Name 3 SERMS
(selective estrogen receptor modulators) |
Tamoxifen
Raloxifene Clomiphene |
|
Tamoxifen use? Risks?
|
Osteoporosis protection, adjuctive treatment to prevent reurrent breast cancer
Thrombosis |
|
Raloxifene location of action
|
Antagonist at breast and endometrium
Agonist at bone |
|
Raloxifene fxn and use
|
Protects agains osteoporosis
Decreased postmenopausal bone reabsorption Decreased incidence of breast cancer |
|
Clomiphene SE and use
|
Enlargment of ovaries
Induction of ovulation *partial estrogen agonist |